drugset / Trial / NCT00779337
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Phase 1
Completed
8 enrolled
Queensland Institute of Medical Research
Australian Department of Industry, Tourism and Resources · collabBritish Society for Haematology · collabNational Health and Medical Research Council, Australia · collabThe Atlantic Philanthropies · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will use a new method of treating lymphoma using a therapy derived from a person's Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. The cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. Potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.
Timeline
- Start
- 2008-10
- Primary completion
- 2012-01
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous AdE1- Latent Membrane Protein CTLs | Cell therapy | 5e+06 cells | Intravenous |
| Subject | Autologous AdE1- Latent Membrane Protein CTLs | Cell therapy | 2e+08 cells | Intravenous |